Aurinia Pharmaceuticals Inc. Financial Assets At Amortised Cost
Aurinia Pharmaceuticals Inc. (AUPH) had Financial Assets At Amortised Cost of $8.00 thousand as of 2018-12-31, per its 40-F filed 2020-03-05.
Discontinued › Notes
ifrs-full:FinancialAssetsAtAmortisedCost · last filed 2020-03-05
- 2018-12-31: Financial Assets At Amortised Cost $8.00K; Financial Assets At Amortised Cost as first filed $7.89M.
| Period end | Financial Assets At Amortised Cost | Financial Assets At Amortised Cost as first filed |
|---|---|---|
| 2018-12-31 | $8.00K 40-F · filed 2020-03-05 | $7.89M 40-F · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |